Sort
10,766 grants matching “checkpoint inhibitor”
Tumor Suppressor Qualities and Mechanisms of LZAP Activity
$416,250Wendell G Yarbrough · Yale University · R01 · FY2015 · DE
Tumor Suppressor Qualities and Mechanisms of LZAP Activity
$416,250Wendell G Yarbrough · Yale University · R01 · FY2016 · DE
Boosting Oncolytic HSV Immunotherapy by Enabling Necroptosis
$416,040Hongyan Guo · Louisiana State Univ Hsc Shreveport · R21 · FY2025 · CA
Collaborative Research: Integrative Adaptation of Dendrimer-peptide Conjugates for Cancer Immunotherapy
$415,969Seungpyo Hong · University Of Wisconsin-Madison · · FY2022 · MPS
Targeting the cytokine circuitry of KRAS-driven lung cancer
$415,743David A Barbie · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Targeting the cytokine circuitry of KRAS-driven lung cancer
$415,743David A Barbie · Dana-Farber Cancer Inst · R01 · FY2020 · CA
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
$415,572Joseph Kissil · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Project 2: Reversing STING-mediated immunosuppression in LKB1-mutant lung adenocarcinoma
$415,518Haian Fu · Emory University · P01 · FY2024 · CA
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in Children
$415,499Yin Wang · University Of Maryland Baltimore · R01 · FY2020 · CA
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer
$415,275Bruce E Clurman · Fred Hutchinson Cancer Research Center · R01 · FY2017 · CA
Enhancing CAR-T cell therapy through theranostic targeted radionuclide therapy
$415,260Yanping Yang · Methodist Hospital Research Institute · R21 · FY2024 · CA
Role of type 2 immune response in pancreatic cancer tumorigenesis
$415,258Prasenjit Dey · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia
$415,196Lili Wang · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Centrosomal and centrosome-independent mechanisms in mitotic spindle assembly
$415,114Alexey L Khodjakov · Wadsworth Center · R01 · FY2015 · GM
Centrosomal and centrosome-independent mechanisms in mitotic spindle assembly
$415,114Alexey L Khodjakov · Wadsworth Center · R01 · FY2017 · GM
Centrosomal and centrosome-independent mechanisms in mitotic spindle assembly
$415,114Alexey L Khodjakov · Wadsworth Center · R01 · FY2016 · GM
Centrosomal and centrosome-independent mechanisms in mitotic spindle assembly
$415,114Alexey L Khodjakov · Wadsworth Center · R01 · FY2014 · GM
Project 3: Chronic interferon and bile acid signaling as drivers of immunosuppression in age-related liver cancer
$415,068Susan M Kaech · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2022 · AG
Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging
$415,067Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2022 · AG
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN
$415,046Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN
$415,045Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA
Role of Macrophage in Osteoimmunology with Aging
$415,033Zhenqiang Yao · University Of Rochester · R01 · FY2024 · AG
Transplanting Unique Human Microbiomes to Improve Immunotherapy in Glioblastoma
$415,031Braden Cox McFarland · University Of Alabama At Birmingham · R21 · FY2021 · CA
A Regulatory Checkpoint in the Pathogenesis of Inflammatory Arthritis
$414,833Christian Stehlik · Northwestern University At Chicago · R01 · FY2016 · AR
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers
$414,529Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2022 · CA